![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
TTX-810 is an IND-enabling candidate, a MCL1 inhibitor, a highly potent and selective macrocyclic compound to treat patients with solid tumor or hematological cancers.
Lead Product(s): TTX-810
Therapeutic Area: Oncology Product Name: TTX-810
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Broad Institute of Harvard
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2023